Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

REGENXBIO Inc. - Common Stock (NQ: RGNX )

7.300 -0.020 (-0.27%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about REGENXBIO Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
The Latest Analyst Ratings for Regenxbio
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 2, 2023
Via Benzinga
Regenxbio's Return On Capital Employed Insights
Via Benzinga
Analyst Expectations for Regenxbio's Future
Via Benzinga
Does an FDA Fast Track Designation Make Regenxbio Stock a Buy Now?
The company focuses on using its technology for gene-editing therapies. 
Via The Motley Fool
Tesla To Rally Over 16%? Here Are 10 Other Analyst Forecasts For Monday
Citigroup raised the price target for The Manitowoc Company, Inc. (NYSE: MTW) from $11 to $21. Citigroup analyst Timothy Thein maintained a Neutral rating. Manitowoc shares fell 2.4% to $19.09 in... 
Via Benzinga
Earnings Preview: Regenxbio
Via Benzinga
Looking Into Regenxbio's Return On Capital Employed
Via Benzinga
Why RH Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers GD Culture Group Limited (NASDAQ: GDC) shares climbed 121.9% to $9.63 after gaining over 8% on Monday. GD Culture recently announced an $11.55 million registered direct offering. 
Via Benzinga
3D Systems, CarGurus, Sarepta Therapeutics And Other Big Stocks Moving Higher On Wednesday
U.S. stocks traded lower, with the Dow Jones dropping around 80 points on Wednesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
5 Analysts Have This to Say About Regenxbio
Via Benzinga
What 5 Analyst Ratings Have To Say About Regenxbio
Within the last quarter, Regenxbio (NASDAQ:RGNX) has observed the following analyst ratings: 
Via Benzinga
Earnings Scheduled For February 28, 2023
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report earnings for its fourth quarter. 
Via Benzinga
Regenxbio Says Diabetic Retinopathy Gene Therapy Shows Meaningful Improvements In Disease Severity
Via Benzinga
Recap: Regenxbio Q3 Earnings
Regenxbio (NASDAQ:RGNX) reported its Q3 earnings results on Thursday, November 3, 2022 at 07:05 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Despite Solid Efficacy From Gene Therapy, This Analyst Cuts REGENXBIO's Price Target
Via Benzinga
One in Five Americans Who Have Been Infected With the Virus Said to Have Long COVID
Palm Beach, FL – November 17, 2022 – FinancialNewsMedia.com News Commentary – Since the beginning of the pandemic, the critical effort of researchers is to understand how coronavirus damages the body.... 
Via FinancialNewsMedia
Exposures COVID-19
Regenxbio's Earnings Outlook
Regenxbio (NASDAQ:RGNX) is set to give its latest quarterly earnings report on Thursday, 2022-11-03. Here's what investors need to know before the announcement. Analysts estimate that Regenxbio will... 
Via Benzinga
Alphabet To $114? Plus This Analyst Predicts $145 For Disney
B of A Securities cut Alphabet Inc. (NASDAQ: GOOGL) price target from $125 to $114. Alphabet shares rose 1.9% to $100.50 in pre-market trading. 
Via Benzinga
What 4 Analyst Ratings Have To Say About Regenxbio
Within the last quarter, Regenxbio (NASDAQ:RGNX) has observed the following analyst ratings: 
Via Benzinga
4 Analysts Have This to Say About Regenxbio
  Regenxbio (NASDAQ:RGNX) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Expert Ratings for Regenxbio
Analysts have provided the following ratings for Regenxbio (NASDAQ:RGNX) within the last quarter: 
Via Benzinga
Earnings Scheduled For November 3, 2022
Companies Reporting Before The Bell • Hyatt Hotels (NYSE:H) is estimated to report quarterly earnings at $0.28 per share on revenue of $1.45 billion. 
Via Benzinga
Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Regenxbio's Earnings Outlook
Regenxbio (NASDAQ:RGNX) is set to give its latest quarterly earnings report on Wednesday, 2022-08-03. Here's what investors need to know before the announcement. Analysts estimate that Regenxbio will... 
Via Benzinga
5 Small-Cap S&P Stocks To Buy With The Most Upside
The S&P 500 is one of the most popular U.S. stock indices and is often what investors and experts are referring to when they mention the "stock market." However, there's more to the market than... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 23, 2022
Upgrades 
Via Benzinga
Regenxbio's Return On Capital Employed Overview
Regenxbio (NASDAQ:RGNX) brought in sales totaling $22.22 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 126.09%, resulting in a loss of $76.72 million. 
Via Benzinga
Expert Ratings for Regenxbio
Over the past 3 months, 4 analysts have published their opinion on Regenxbio (NASDAQ:RGNX) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a... 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback